Neuromyelitis optica spectrum disorder with anti-AQP4 antibodies
MONDO:0035663Also known as: NMOSD with anti-AQP4 antibodies, Neuromyelitis optica spectrum disorder with anti-aquaporin 4 antibodies
5 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New hope for kids with rare nerve disease: satralizumab trial begins
Disease control Recruiting nowThis study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New registry study tests antibody drugs for rare nerve disease
Disease control Recruiting nowThis registry study is tracking 200 people with a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) who are positive for the AQP4 antibody. Researchers are evaluating how well monoclonal antibody therapies work in real-world settings, focusing on preve…
Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:35 UTC
-
New registry to monitor Real-World effects of NMOSD treatments
Knowledge-focused Recruiting nowThis study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs like eculizumab or ravulizumab. It will collect information on relapses, safety, and quality of life over many years to unders…
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC